Gapping up
In reaction to earnings/guidance:
- VRAY +36.1%
Other news:
- FLIR +21.8% (to be acquired by TDY)
- BPY +15.9% (Brookfield Asset Management (BAM) has made proposal to acquire all of the limited partnership units of BPY that it does not already own at a value of $16.50/share)
- MGLN +11.8% (Magellan Health: Centene (CNC) signs definitive agreement to acquire Magellan Health for $95 per share in cash for a total enterprise value of $2.2 billion)
- ENZ +11.5% (received an expansion of its EUA from the FDA authorizing the use of pooled samples containing up to five individual swab specimens with its AMPIPROBE SARS-Cov-2 Test System utilizing tests on three different platforms including Enzo's proprietary GENFLEX automated high-throughput platform)
- MOGO +10.3% (enters into at-the-market offering agreement; reports over 100% increase in new bitcoin accounts in December)
- CTSO +6.6% (announces that Health Canada has granted Medical Device Authorization for the importation, sale, and emergency use of CytoSorb in hospitalized COVID-19 patients under Interim Order 316575)
- XPEV +6.1% (reports December deliveries increased 326% yr/yr)
- MEIP +6.1% (expands Phase 1b Study evaluating Zandelisib)
- LI +5.3% (reports December deliveries increased 529.6% yr/yr)
- MTNB +5.1% (FDA has conditionally accepted LYPDISO as the proposed brand name for MAT9001)
- KXIN +4.6% (entered into a definitive share purchase agreement with the shareholders of Haitaoche Limited on December 31, 2020)
- NGA +4.6% (announces filing by The Lion Electric Company of a preliminary registration statement on SEC Form F-4 in connection with their proposed business combination)
- GDX +4% (gold futures up nearly 2%)
- ARCT +4% (receives FDA allowance to proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) vaccine candidate)
- NIO +3.4% (reports Decemeber deliveries increased 121.0% yr/yr to 7,007 vehicles)
- GORO +3.1% (announces leadership updates in conjunction with spin-off of Nevada Mining Unit)
- SLV +2.9% (in line with silver futures)
- BBIO +2.7% (Proxy advisory firm ISS Recommends BridgeBio Pharma and Eidos Therapeutics (EIDX) stockholders vote for proposed merger (special meetings to be held on January 19, 2021)) SSL +2.6% (completes divestment of 50% equity interest in Gemini HDPE)
- OVV +2.6% (provides Q4 update; production of more than 210 thousand barrels per day)
- FSR +2.5% (Fisker will partner with Magna (MGA) for the joint development of FI-Pilot)
- PLTR +2.4% (expands Japan Business with new $22.5 mln contract)
- MRNA +2.4% (to provide business and pipeline updates at the 2021 J.P. Morgan Healthcare Conference Monday, January 11 at 4:30 PM ET )
- MGA +2.3% (announced the appointment of Swamy Kotagiri as Magna's next Chief Executive Officer, effective January 1, 2021)
- UUUU +2.1% (renews "at-the-market" program for the sale of up to an additional US$35.0 mln of common shares)
- TSLA +2.1% (reports Q4 production and delivery results; FY20 results in-line with guidance)
- SABR +1.9% (Sabre and Southwest Airlines announce new full participation distribution agreement)
- GLD +1.6% (in line with gold futures)
- EYPT +1.2% (reports $15.7 mln equity investment by Ocumension Therapeutics)
- PRVB +1.2% (announces US FDA filing of a biologics license application and priority review for teplizumab for the delay or prevention of clinical type 1 diabetes in at-risk individuals)
Analyst comments:
- NWL +2.7% (upgraded to Buy from Hold at Jefferies)
- UAA +1.9% (upgraded to Buy from Hold at Pivotal Research Group)
- ALGN +1.6% (upgraded to Outperform from In-line at Evercore ISI)
- EXPE +1.6% (upgraded to Buy from Neutral at BofA Securities)
- MS +1.6% (upgraded to Overweight from Equal Weight at Barclays)
- T +1.5% (upgraded to Outperform from Mkt Perform at Raymond James)
- ABNB +1.4% (initiated with an Overweight at Piper Sandler, among others)
- GS +1.3% (upgraded to Overweight from Equal Weight at Barclays)
- TAP +1.3% (upgraded to Buy from Hold at Jefferies)
- HSIC +1.2% (upgraded to Outperform from Neutral at Robert W. Baird)
- HIG +1.1% (upgraded to Overweight from Neutral at JP Morgan)
- ALLY +0.8% (upgraded to Overweight from Equal Weight at Barclays)